Is PD-L1 Just the Tip of the Iceberg?
February 1st 2016PD-1 and PD-L1 inhibition offers the possibility for precision immuno-oncology through the application of biomarkers that predict the immune systems response. This principle has been demonstrated by two of the most recent FDA approvals for patients with lung cancer.